Clozapine in Parkinson's disease tremor: Effects of acute and chronic administration

Neurology

Volumn 49, Issue 6, 1997, Pages 1587-1590

  Bonuccelli, Ubaldo ^a   Ceravolo, R ^a   Salvetti, S ^a   D'Avino, C ^a   Del Dotto, P ^a   Rossi, G ^b   Murri, L ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGED; ARTICLE; BETA ADRENERGIC STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; SEDATION; TREATMENT OUTCOME; TREMOR;

EID: 0031438503     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.6.1587     Document Type: Article

References (34)

1. Lance JW, Schwab RS, Peterson EA. Action tremor and the cogwheel phenomenon in Parkinson's disease. Brain 1963;86:95-110.
2. Findley LJ, Gresty MA, Halmagyi GM. Tremor, the cogwheel phenomenon and clonus in Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:534-536.
3. Jankovic J, Frost JD Jr. Quantitative assessment of parkinsonian and essential tremor: clinical application of triaxial accelerometry. Neurology 1981;31:1235-1240.
4. Koller WC, Overfield BV, Barter R. Tremors in early Parkinson's disease. Clin Neuropharmacol 1989;12:293-297.
5. Benabid AL, Pollack P, Seigneuret E, Gay E, Perret J. Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochir Suppl (Wien) 1993;58:39-44.
6. Siegfried J. Therapeutic stereotactic procedures on the thalamus for motor movement disorders. Acta Neurochir (Wien) 1993;124:14-18.
7. Koller W, Hristova A. Efficacy and safety of stereotaxic surgical treatment of tremor disorders. Eur J Neurol 1996;3:507-514.
8. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239-242.
9. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-546.
10. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297.
11. Fischer PA, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm 1990;2:233-238.
12. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-229.
13. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-265.
14. Korsgaard CH, Regeur L, Werdelin L. Clozapine in the treatment of tremor: clinical experience since 1986 (abstract). Mov Disord 1994;9(suppl 1):20.
15. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-1081.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
17. Hallett M. Differential diagnosis of tremor. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology, vol 5. Extrapyramidal disorders. Amsterdam: Elsevier, 1986:583-595.
18. Elble RJ. The pathophysiology of tremor. In: Watts RL, Koller WC, eds. Movement disorders: neurologic principles and practice. New York: McGraw-Hill, 1997:405-417.
19. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
20. Lang AET, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Stoneham, MA: Butterworth, 1989:285-301.
21. Lamarre Y. Animal models of tremors. In: Findley LJ, Capildeo R, eds. Movement disorders: tremor. London: MacMillan Press, 1984:183-184.
22. Lamarre Y, Joffroy AJ. Experimental tremor in the monkey: activity of thalamic and precentral cortical neurons in the absence of peripheral feedback. Adv Neurol 1979;24:109-122.
23. Young RR, Growdon JH, Shahani BT. Beta-adrenergic mechanisms in action tremor. N Engl J Med 1975;293:950-953.
24. Fahn S. Pharmacological differentiation of tremor. In: Findley LJ, Capildeo R, eds. Movement disorders: tremor. London: MacMillan, 1984:85-93.
25. Findley LJ. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1993:293-313.
26. Young RR. Essential-familial tremor. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology, vol. 5: extrapyramidal disorders. Amsterdam: Elsevier, 1986:565-581.
27. Sandler M. The dopa effect: possible significance of transamination and tetrahydroisoquinoline formation. In: Yahr MD, ed. Treatment of parkinsonism: the role of dopa decarboxylase inhibitors. Adv Neurol 1973;2:255-264.
28. Biedert S, Walter-Rudi S, Muller-Wulff I. Low-dose clozapine and tetrabenazine in the treatment of essential tremor and oral-facial dyskinesia (abstract). Mov Disord 1994;9(suppl 1):23.
29. McCarthy RH. Clozapine reduces essential tremor independent of its antipsychotic effect: a case report. J Clin Psychopharmacol 1994;14:212-213.
30. Ceravolo R, Salvetti S, Dell'Agnello G, D'Avino C, Bonuccelli U. Pharmacological tools in the study of essential tremor (abstract). Mov Disord 1996;11(suppl 1):P963.
31. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55:47-52.
32. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994;44:821-823.
33. Mai J, Olsen RB. Depression of essential tremor by alpha-adrenergic blockade (letter). J Neurol Neurosurg Psychiatry 1981;44:1171.
34. Blond S, Caparros-Lefebvre D, Parker F, et al. Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. J Neurosurg 1992;77:62-68.